Oncology Companion Diagnostics Market Size, Share, Trends, Growth Outlook

Oncology Companion Diagnostics Market is estimated to increase at a growth rate of 12.4% CAGR over the forecast period from 2024 to 2030.

The global Oncology Companion Diagnostics Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product & Services (Product, Service ), By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH), Fluorescence in situ hybridization (FISH), Others), By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others), By End-user (Hospital, Pathology/Diagnostic laboratory, Academic medical center).

An introduction to Oncology Companion Diagnostics Market in 2024

In 2024, the oncology companion diagnostic market is witnessing substantial growth driven by advancements in personalized medicine, precision oncology, and targeted therapies. Companion diagnostics play a pivotal role in identifying patients who are most likely to benefit from specific cancer treatments, enabling healthcare providers to optimize treatment decisions and improve patient outcomes. With the increasing adoption of biomarker-driven therapies and regulatory incentives for companion diagnostic development, the market is experiencing rapid expansion, fostering collaborations between pharmaceutical companies, diagnostic manufacturers, and healthcare institutions to enhance the clinical utility and accessibility of oncology companion diagnostics.

Oncology Companion Diagnostics Market Trend: Rise in Personalized Medicine

A prominent trend in the Oncology Companion Diagnostics Market is the increasing adoption of personalized medicine. With advancements in genomic profiling and molecular diagnostics, there's a growing emphasis on identifying specific genetic mutations or biomarkers in cancer patients to guide treatment decisions. Oncology companion diagnostics play a pivotal role in personalized cancer therapy by matching patients with targeted therapies or immunotherapies based on their molecular profile, thus optimizing treatment outcomes and minimizing adverse effects. This trend towards personalized medicine drives the demand for companion diagnostics in oncology, shaping the landscape of cancer treatment towards more precise and effective interventions.

Oncology Companion Diagnostics Market Driver: Shift Towards Targeted Therapies and Precision Oncology

A significant driver propelling the Oncology Companion Diagnostics Market is the shift towards targeted therapies and precision oncology. Traditional chemotherapy approaches are being complemented or replaced by targeted therapies that selectively target cancer cells based on specific molecular alterations. Companion diagnostics are essential tools for identifying patients who are most likely to benefit from targeted therapies, enabling healthcare providers to personalize treatment decisions and optimize patient outcomes. The increasing adoption of precision oncology strategies in clinical practice drives the demand for companion diagnostics, fueling market growth and innovation in molecular testing technologies and assay development.

Market Opportunity Expansion into Liquid Biopsy Companion Diagnostics

An enticing opportunity within the Oncology Companion Diagnostics Market lies in the expansion into liquid biopsy companion diagnostics. Liquid biopsy, a minimally invasive diagnostic approach that analyzes tumor-derived biomarkers circulating in blood or other body fluids, offers several advantages over traditional tissue biopsy, including real-time monitoring of disease progression, assessment of treatment response, and detection of molecular changes associated with resistance to therapy. By developing companion diagnostic tests for liquid biopsy-based biomarkers, companies can provide non-invasive and dynamic monitoring solutions for cancer patients, facilitating early detection of treatment resistance and guiding treatment adjustments. Expanding into liquid biopsy companion diagnostics presents an opportunity to address unmet needs in cancer management, enhance patient care, and capitalize on the growing adoption of liquid biopsy technologies in oncology clinical practice.

Oncology Companion Diagnostics Market Market Segmentation

By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Oncology Companion Diagnostics Market Companies

Abbott
Agilent Technologies Inc
ARUP Laboratories
bioMérieux SA
F. Hoffmann-La Roche Ltd
Illumina Inc
Invivoscribe Inc
Myriad Genetics Inc
QIAGEN N.V.
Roche Ltd
Thermo Fisher Scientific Inc

Reasons to Buy the Oncology Companion Diagnostics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Oncology Companion Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Oncology Companion Diagnostics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Oncology Companion Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Oncology Companion Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Oncology Companion Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Oncology Companion Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Oncology Companion Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Oncology Companion Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Oncology Companion Diagnostics Industry
4.2 Key Market Trends in Oncology Companion Diagnostics Industry
4.3 Potential Opportunities in Oncology Companion Diagnostics Industry
4.4 Key Challenges in Oncology Companion Diagnostics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Oncology Companion Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Oncology Companion Diagnostics Market Outlook by Segments
7.1 Oncology Companion Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

8 North America Oncology Companion Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Oncology Companion Diagnostics Markets in 2024
8.2 North America Oncology Companion Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Oncology Companion Diagnostics Market size Outlook by Segments, 2021-2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

9 Europe Oncology Companion Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Oncology Companion Diagnostics Markets in 2024
9.2 Europe Oncology Companion Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Oncology Companion Diagnostics Market Size Outlook by Segments, 2021-2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

10 Asia Pacific Oncology Companion Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Oncology Companion Diagnostics Markets in 2024
10.2 Asia Pacific Oncology Companion Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Oncology Companion Diagnostics Market size Outlook by Segments, 2021-2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

11 South America Oncology Companion Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Oncology Companion Diagnostics Markets in 2024
11.2 South America Oncology Companion Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Oncology Companion Diagnostics Market size Outlook by Segments, 2021-2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

12 Middle East and Africa Oncology Companion Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Oncology Companion Diagnostics Markets in 2024
12.2 Middle East and Africa Oncology Companion Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Oncology Companion Diagnostics Market size Outlook by Segments, 2021-2030
By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott
Agilent Technologies Inc
ARUP Laboratories
bioMérieux SA
F. Hoffmann-La Roche Ltd
Illumina Inc
Invivoscribe Inc
Myriad Genetics Inc
QIAGEN N.V.
Roche Ltd
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product & Service
Product
-Instrument
-Consumables
-Software
Service
By Technology
Polymerase chain reaction (PCR)
Next-generation sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type
Breast cancer
Non-small cell lung cancer
Colorectal cancer
Leukemia
Melanoma
Prostate cancer
Others
By End-user
Hospital
Pathology/Diagnostic laboratory
Academic medical center